GlassScriptPhysician profile
Panagiotis Mitropoulos
NPI 1538283502
$30,968.07
in general payments reported to CMS, 2019-2025
40 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $1,570 · 2021: $1,478 · 2022: $2,317 · 2023: $2,645 · 2024: $4,283 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,663 · Consulting Fee: $1,400 · Education: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,063.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,663.00 |
| Consulting Fee | $1,400.00 |
| Education | $566.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $10,859.12 | 2019-2025 | Tremfya |
| Abbvie INC. | $2,550.27 | 2019-2025 | |
| Botanix Sb INC | $1,674.59 | 2025 | Sofdra |
| Genzyme Corporation | $1,307.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,297.64 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $1,268.41 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,167.56 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $1,144.75 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $960.71 | 2023-2024 | Vtama |
| Lilly USA, LLC | $911.52 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $883.76 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $857.58 | 2021-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $808.56 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $780.11 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $597.34 | 2021-2025 | Opzelura, Opzelura |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $570.22 | 2022-2025 | Sotyktu |
| Genentech USA, INC. | $428.10 | 2019-2023 | Erivedge |
| Pfizer INC. | $334.44 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $313.41 | 2019-2025 | |
| Organon LLC | $308.34 | 2024-2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $304.42 | 2019-2022 | |
| Journey Medical Corporation | $220.83 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $217.33 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Dermira, INC. | $200.52 | 2019-2021 | |
| Allergan, INC. | $195.03 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $144.46 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.62 | 2022-2025 | Spevigo, Cyltezo |
| Vyne Pharmaceuticals INC. | $110.68 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $67.36 | 2024-2025 | Ycanth |
| Almirall LLC | $67.28 | 2021-2022 | |
| Strata Skin Sciences, INC. | $58.41 | 2020-2022 | |
| Blueprint Medicines Corporation | $43.12 | 2025 | Ayvakit |
| Biofrontera INC. | $42.51 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $34.91 | 2019 | |
| Celgene Corporation | $21.55 | 2019 | |
| Encore Dermatology INC. | $18.20 | 2019 | |
| Merz North America, INC. | $17.10 | 2019 | |
| Kerecis Limited | $14.93 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Helsinn Therapeutics (U.S.), INC. | $14.46 | 2023 | Valchlor |
| Epi Health, LLC | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panagiotis Mitropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.